Andere talen CANbridge Pharmaceuticals Inc.

Aandelen

1228

KYG1821D1097

Beurs gesloten - Hong Kong S.E. Andere beurzen 10:08:05 02-07-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
0,32 ^HKD	-3,03%		-3,03%	-67,68%

22/04	CANbridge Pharmaceuticals Inc. Kondigt de resultaten aan van CAN008 Fase II Klinische Studie voor de Behandeling van Glioblastoma Multiforme	CI
28/03	CANbridge Pharmaceuticals Inc. rapporteert resultaten voor het volledige jaar dat eindigde op 31 december 2023	CI

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

Canbridge Pharmaceuticals Shelves Glioblastoma Drug After Phase II Clinical Trials	23/04
CANbridge Pharmaceuticals Inc. Announces Results of CAN008 Phase II Clinical Trial for the Treatment of Glioblastoma Multiforme	22/04
CANbridge Pharmaceuticals Inc. Announces Change of Principal Place of Business in Hong Kong, Effect from April 15, 2024	12/04
CANbridge Pharmaceuticals Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	28/03
CANbridge and PUMCH announced the establishment of PUMCH, CANbridge Genetic Defect Rare Disease Innovation and Translation Base	04/03
CANbridge Pharmaceuticals Grants Share Options, Restricted Shares	08/02
CANbridge Pharmaceuticals Inc. Announces Resignation of Derek Paul Di Rocco as Non-Executive Director and A Member of the Nomination and Corporate Governance Committee	23/11
CANbridge Pharmaceuticals - Foundation consolidated over time and for a rosy future, 2023 China Conference on Rare Diseases closed successfully	07/11
CANbridge Pharmaceuticals to Present Fabry Disease Gene Therapy Abstract at ESGCT 30th Annual Congress	26-10-23
CANbridge Pharmaceuticals Inc. to Present Fabry Disease Gene Therapy Abstract At Esgct 30Th Annual Congress	25-10-23
CANbridge Announces NDA Acceptance of CAN108 for Cholestatic Pruritus in Progressive Familial Intrahepatic Cholestasis by China's National Medical Products Administration	18-10-23
CANbridge Announces NDA Acceptance of CAN108 (®/LIVMARLI®) for Cholestatic Pruritus in Progressive Familial Intrahepatic Cholestasis by China's National Medical Products Administration	17-10-23
CANbridge Announces Full Enrollment Reached in the Core Part of the CAN103 Phase 2 trial for Gaucher Disease in China	16-10-23
Canbridge Pharmaceuticals Inc. Announces Full Enrollment Reached in the Core Part of the Can103 Phase 2 Trial for Gaucher Disease in China	16-10-23
CANbridge Announces Marketing Approval of CAN108 in Taiwan for the Treatment of Cholestatic Pruritus in Patients with Alagille Syndrome	09-10-23
Canbridge Pharmaceuticals Inc. Announces Marketing Approval of Can108 (Maralixibat Chloride Oral Solution /Livmarli®?) in Taiwan for the Treatment of Cholestatic Pruritus in Patients with Alagille Syndrome	09-10-23
CANbridge to Participate in Two Investor Conferences in September	07-09-23
CANbridge Pharmaceuticals' H1 Attributable Loss Narrows	31-08-23
CANbridge Pharmaceuticals Inc. Reports Earnings Results for the Half Year Ended June 30, 2023	31-08-23
CANbridge Pharmaceuticals Releases Phase 1B Data for Red Blood Cell Disorder Treatment	26-06-23

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen CANbridge Pharmaceuticals Inc.

Aandelen

1228

KYG1821D1097

Andere talen

Filters